Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma

Journal of Pathology

Volumn 224, Issue 2, 2011, Pages 270-279

  Al Ahmadie, Hikmat A ^a   Iyer, Gopa ^a   Janakiraman, Manickam ^a   Lin, Oscar ^a   Heguy, Adriana ^a   Tickoo, Satish K ^a,b   Fine, Samson W ^a   Gopalan, Anuradha ^a   Chen, Ying Bei ^a   Balar, Arjun ^a   Riches, Jamie ^a   Bochner, Bernard ^a   Dalbagni, Guido ^a   Bajorin, Dean F ^a,b   Reuter, Victor E ^a,b   Milowsky, Matthew I ^a,b   Solit, David B ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

FGFR 3; fibroblast growth factor receptor 3; morphology; urothelial carcinoma

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ARTICLE; CANCER GRADING; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; SOMATIC MUTATION; TRANSITIONAL CELL CARCINOMA;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 79955788046     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2892     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al., Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Cookson MS, Herr HW, Zhang ZF, et al., The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158: 62-67. (Pubitemid 27251595)
3. Grossman HB, O'Donnell MA, Cookson MS, et al., Bacillus calmette-guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol 2008; 10: 281-289.
4. Stein JP, Lieskovsky G, Cote R, et al., Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19: 666-675. (Pubitemid 32120143)
5. Milowsky MI, Stadler WM, Bajorin DF,. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int 2008; 102: 1339-1344.
6. Jordan AM, Weingarten J, Murphy WM,. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 1987; 60: 2766-2774. (Pubitemid 17161810)
7. Herr HW,. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000; 163:60-1, discussion 1-2.
8. Smits G, Schaafsma E, Kiemeney L, et al., Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology 1998; 52: 1009-1013, discussion 13-14.
9. Herr HW,. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997; 80: 762-765. (Pubitemid 28316341)
10. Botteman MF, Pashos CL, Redaelli A, et al., The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-1330. (Pubitemid 38041357)
11. Sievert K, Amend B, Nagele U, et al., Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009; 27: 295-300.
12. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
13. Hudis CA,. Trastuzumabâmechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51. (Pubitemid 47026733)
14. Van Cutsem E, Kohne CH, Hitre E, et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
15. Hurwitz H, Fehrenbacher L, Novotny W, et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
16. Geyer CE, Forster J, Lindquist D, et al., Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743. (Pubitemid 46021510)
17. Knowles MA,. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007; 25 (6): 581-593.
18. Cappellen D, De Oliveira C, Ricol D, et al., Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23: 18-20.
19. di Martino E, L'Hote CG, Kennedy W, et al., Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 2009; 28: 4306-4316.
20. Billerey C, Chopin D, Aubriot-Lorton MH, et al., Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158: 1955-1959. (Pubitemid 32545179)
21. Hernandez S, Lopez-Knowles E, Lloreta J, et al., Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006; 24: 3664-3671. (Pubitemid 46630542)
22. van Rhijn BW, Vis AN, van der Kwast TH, et al., Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003; 21: 1912-1921. (Pubitemid 46606378)
23. Epstein JI, Amin MB, Reuter VR, et al., The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-1448. (Pubitemid 28550639)
24. Pratilas CA, Hanrahan AJ, Halilovic E, et al., Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008; 68: 9375-9383.
25. Janakiraman M, Vakiani E, Zeng Z, et al., Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010; 70: 5901-5911.
26. Al-Ahmadie HA, Lin O, Iyer GV, et al., Unique morphologic characteristics of high grade urothelial carcinoma with fibroblast growth factor receptor-3 (FGFR3) gene mutations. Mod Pathol 2010; 23: 768.
27. Tomlinson DC, Baldo O, Harnden P, et al., FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213: 91-98. (Pubitemid 47354570)
28. Kimura T, Suzuki H, Ohashi T, et al., The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 2001; 92: 2555-2561. (Pubitemid 33049438)
29. Druker BJ,. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808-4817.
30. Demetri GD, von Mehren M, Blanke CD, et al., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480. (Pubitemid 34879334)
31. Demetri GD,. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematol Oncol Clin North Am 2002; 16: 1115-1124. (Pubitemid 35462917)
32. Tsao MS, Sakurada A, Cutz JC, et al., Erlotinib in lung cancerâmolecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144. (Pubitemid 41058345)
33. Flaherty KT, Puzanov I, Kim KB, et al., Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
34. Roberts PJ, Stinchcombe TE, Der CJ, et al., Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010; 28: 4769-4777.
35. Pao W, Wang TY, Riely GJ, et al., KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2 (1): e17.
36. Barton S, Starling N, Swanton C,. Predictive molecular markers of response to epidermal growth factor receptor (EGFR) family-targeted therapies. Curr Cancer Drug Targets 2010; 10 (8): 799-812.
37. Haugsten EM, Wiedlocha A, Olsnes S, et al., Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 2010; 8 (11): 1439-1452.
38. van Rhijn BW, van Tilborg AA, Lurkin I, et al., Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 2002; 10: 819-824. (Pubitemid 36054563)
39. Webster MK, Donoghue DJ,. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997; 13: 178-182. (Pubitemid 27219582)
40. Tomlinson DC, Hurst CD, Knowles MA,. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007; 26 (40): 5889-5899.